| GTO ID | GTC2894 |
| Trial ID | NCT05195294 |
| Disease | Hepatocellular Carcinoma |
| Altered gene | HBV gene |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | LioCyx-M |
| HLA | HLA class I |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Multi-center, Phase 1b/2 Study for Autologous T Cells Transfected With mRNA Encoding HBV Antigen-specific TCR (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for Advanced HBV-related Hepatocellular Carcinoma |
| Year | 2021 |
| Country | Singapore |
| Company sponsor | Lion TCR Pte. Ltd. |
| Other ID(s) | LTCR-HCC-3-4 |
| Cohort1: LioCyx-M | |||||||||
|
|||||||||
| Cohort2: LioCyx-M_Lenvatinib | |||||||||
|
|||||||||